![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RP2 |
Gene summary for RP2 |
![]() |
Gene information | Species | Human | Gene symbol | RP2 | Gene ID | 6102 |
Gene name | RP2 activator of ARL3 GTPase | |
Gene Alias | DELXp11.3 | |
Cytomap | Xp11.3 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A1B2JLU2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6102 | RP2 | HCC1_Meng | Human | Liver | HCC | 3.70e-16 | -1.45e-02 | 0.0246 |
6102 | RP2 | HCC2_Meng | Human | Liver | HCC | 2.51e-10 | 3.31e-02 | 0.0107 |
6102 | RP2 | HCC1 | Human | Liver | HCC | 8.75e-20 | 4.36e+00 | 0.5336 |
6102 | RP2 | S027 | Human | Liver | HCC | 4.76e-05 | 6.01e-01 | 0.2446 |
6102 | RP2 | S028 | Human | Liver | HCC | 3.73e-10 | 5.30e-01 | 0.2503 |
6102 | RP2 | S029 | Human | Liver | HCC | 1.76e-16 | 7.54e-01 | 0.2581 |
6102 | RP2 | male-WTA | Human | Thyroid | PTC | 4.35e-04 | -1.97e-02 | 0.1037 |
6102 | RP2 | PTC04 | Human | Thyroid | PTC | 1.81e-02 | 1.34e-02 | 0.1927 |
6102 | RP2 | PTC07 | Human | Thyroid | PTC | 1.52e-06 | 1.42e-02 | 0.2044 |
6102 | RP2 | ATC12 | Human | Thyroid | ATC | 2.64e-02 | -4.87e-03 | 0.34 |
6102 | RP2 | ATC13 | Human | Thyroid | ATC | 4.65e-23 | 9.51e-02 | 0.34 |
6102 | RP2 | ATC2 | Human | Thyroid | ATC | 5.54e-15 | 1.02e+00 | 0.34 |
6102 | RP2 | ATC5 | Human | Thyroid | ATC | 3.28e-12 | 1.14e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006457112 | Thyroid | PTC | protein folding | 137/5968 | 212/18723 | 8.29e-23 | 2.01e-20 | 137 |
GO:0045732113 | Thyroid | PTC | positive regulation of protein catabolic process | 142/5968 | 231/18723 | 1.43e-20 | 2.38e-18 | 142 |
GO:2001233113 | Thyroid | PTC | regulation of apoptotic signaling pathway | 197/5968 | 356/18723 | 2.58e-20 | 3.69e-18 | 197 |
GO:1903364113 | Thyroid | PTC | positive regulation of cellular protein catabolic process | 104/5968 | 155/18723 | 1.93e-19 | 2.39e-17 | 104 |
GO:0097193113 | Thyroid | PTC | intrinsic apoptotic signaling pathway | 164/5968 | 288/18723 | 9.17e-19 | 1.09e-16 | 164 |
GO:2001242113 | Thyroid | PTC | regulation of intrinsic apoptotic signaling pathway | 99/5968 | 164/18723 | 4.74e-14 | 2.79e-12 | 99 |
GO:0016049112 | Thyroid | PTC | cell growth | 225/5968 | 482/18723 | 4.75e-12 | 2.07e-10 | 225 |
GO:000689218 | Thyroid | PTC | post-Golgi vesicle-mediated transport | 66/5968 | 104/18723 | 3.36e-11 | 1.24e-09 | 66 |
GO:1905897113 | Thyroid | PTC | regulation of response to endoplasmic reticulum stress | 52/5968 | 82/18723 | 4.18e-09 | 1.10e-07 | 52 |
GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
GO:0071900110 | Thyroid | PTC | regulation of protein serine/threonine kinase activity | 164/5968 | 359/18723 | 2.41e-08 | 5.43e-07 | 164 |
GO:001072018 | Thyroid | PTC | positive regulation of cell development | 138/5968 | 298/18723 | 1.13e-07 | 2.22e-06 | 138 |
GO:000184118 | Thyroid | PTC | neural tube formation | 58/5968 | 102/18723 | 1.59e-07 | 3.03e-06 | 58 |
GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
GO:006156419 | Thyroid | PTC | axon development | 199/5968 | 467/18723 | 5.27e-07 | 8.53e-06 | 199 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
GO:007005925 | Thyroid | PTC | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 39/5968 | 63/18723 | 8.90e-07 | 1.35e-05 | 39 |
GO:000717819 | Thyroid | PTC | transmembrane receptor protein serine/threonine kinase signaling pathway | 156/5968 | 355/18723 | 1.02e-06 | 1.51e-05 | 156 |
GO:000183817 | Thyroid | PTC | embryonic epithelial tube formation | 64/5968 | 121/18723 | 1.27e-06 | 1.83e-05 | 64 |
GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
SEMA3D | NRP2_PLXNA2 | SEMA3D_NRP2_PLXNA2 | SEMA3 | Breast | ADJ |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Breast | DCIS |
SEMA3C | NRP2_PLXNA2 | SEMA3C_NRP2_PLXNA2 | SEMA3 | Breast | Healthy |
SEMA3D | NRP2_PLXNA2 | SEMA3D_NRP2_PLXNA2 | SEMA3 | Breast | Healthy |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Breast | Healthy |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Cervix | ADJ |
SEMA3C | NRP2_PLXNA2 | SEMA3C_NRP2_PLXNA2 | SEMA3 | Cervix | CC |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | Cervix | CC |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Cervix | CC |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Cervix | Precancer |
SEMA3C | NRP2_PLXNA2 | SEMA3C_NRP2_PLXNA2 | SEMA3 | CRC | AD |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | CRC | AD |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | CRC | AD |
SEMA3B | NRP2_PLXNA2 | SEMA3B_NRP2_PLXNA2 | SEMA3 | CRC | ADJ |
SEMA3C | NRP2_PLXNA2 | SEMA3C_NRP2_PLXNA2 | SEMA3 | CRC | ADJ |
SEMA3B | NRP2_PLXNA2 | SEMA3B_NRP2_PLXNA2 | SEMA3 | CRC | FAP |
SEMA3C | NRP2_PLXNA2 | SEMA3C_NRP2_PLXNA2 | SEMA3 | CRC | FAP |
SEMA3B | NRP2_PLXNA2 | SEMA3B_NRP2_PLXNA2 | SEMA3 | CRC | MSI-H |
SEMA3C | NRP2_PLXNA2 | SEMA3C_NRP2_PLXNA2 | SEMA3 | CRC | MSI-H |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | CRC | MSI-H |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RP2 | SNV | Missense_Mutation | c.44C>G | p.Ser15Trp | p.S15W | O75695 | protein_coding | deleterious(0.01) | benign(0.176) | TCGA-BH-A208-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RP2 | SNV | Missense_Mutation | c.884G>A | p.Gly295Asp | p.G295D | O75695 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-GM-A2DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | CR | |
RP2 | SNV | Missense_Mutation | c.874C>A | p.Leu292Met | p.L292M | O75695 | protein_coding | deleterious(0.05) | possibly_damaging(0.468) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
RP2 | SNV | Missense_Mutation | novel | c.176N>A | p.Gly59Glu | p.G59E | O75695 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RP2 | SNV | Missense_Mutation | c.301N>C | p.Phe101Leu | p.F101L | O75695 | protein_coding | deleterious(0) | possibly_damaging(0.893) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
RP2 | SNV | Missense_Mutation | c.628G>A | p.Val210Ile | p.V210I | O75695 | protein_coding | tolerated(0.24) | benign(0) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RP2 | SNV | Missense_Mutation | c.467N>A | p.Ala156Asp | p.A156D | O75695 | protein_coding | tolerated(0.44) | benign(0.045) | TCGA-AG-4015-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RP2 | SNV | Missense_Mutation | novel | c.521N>C | p.Ile174Thr | p.I174T | O75695 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RP2 | SNV | Missense_Mutation | novel | c.721T>G | p.Phe241Val | p.F241V | O75695 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RP2 | SNV | Missense_Mutation | novel | c.536N>A | p.Pro179His | p.P179H | O75695 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |